Mylan N.V. (MYL +6%) has restarted production
of hydroxychloroquine sulfate tablets at its West Virginia facility in
order to meet COVID-19-related demand, although it is not formerly
approved for this use (currently authorized to treat malaria, lupus
erythematosus and rheumatoid arthritis).
It is also taking steps to initiate production
ex-U.S. in the coming weeks, adding that it expects to begin supplying
product by mid-April and has an inventory of the active ingredient to
potentially treat more than 1.5M patients.
Related tickers: Teva Pharmaceutical Industries (TEVA +8.6%), Amneal Pharmaceuticals (AMRX +18.4%), Novartis (NVS +1.3%), Bayer (OTCPK:BAYRY +2%)
https://seekingalpha.com/news/3553501-mylanplus-6-ramps-up-u-s-production-of-malaria-drug-for-covidminus-19-use
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.